March 31, 2016

Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields

Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in Culture Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in… Read More
learn more
March 31, 2016

Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields

Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in Culture Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in… Read More
learn more
March 31, 2016

Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields

Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in Culture Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in… Read More
learn more
March 9, 2016

Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma

March 09, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that a computational study analyzing the effect of transducer layout on Tumor Treating Fields, or TTFields, distribution has been published in the International Journal… Read More
learn more
March 9, 2016

Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma

March 09, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that a computational study analyzing the effect of transducer layout on Tumor Treating Fields, or TTFields, distribution has been published in the International Journal… Read More
learn more
March 9, 2016

Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma

March 09, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that a computational study analyzing the effect of transducer layout on Tumor Treating Fields, or TTFields, distribution has been published in the International Journal… Read More
learn more
March 3, 2016

Humana Issues Positive Coverage Decision For Optune

More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma March 03, 2016 07:30 AM Eastern Standard Time… Read More
learn more
March 3, 2016

Humana Issues Positive Coverage Decision For Optune

More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma March 03, 2016 07:30 AM Eastern Standard Time… Read More
learn more
March 3, 2016

Humana Issues Positive Coverage Decision For Optune

More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma March 03, 2016 07:30 AM Eastern Standard Time… Read More
learn more